UNITED THERAPEUTICS Corp
For the period ended Mar 31, 2024. Filed May 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 1, 2024
UTHR$582.46+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In millions, except share data)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,251.5 | $1,207.7 |
| Marketable investments | 1,456.3 | 1,786.4 |
| Accounts receivable, no allowance for 2024 and 2023 | 307.3 | 278.9 |
| Inventories, net | 120.2 | 111.8 |
| Other current assets | 113.4 | 166.2 |
| Total current assets | 3,248.7 | 3,551.0 |
| Marketable investments | 1,491.9 | 1,909.8 |
| Goodwill and other intangible assets, net | 115.4 | 114.2 |
| Property, plant, and equipment, net | 1,074.0 | 1,045.4 |
| Deferred tax assets, net | 396.1 | 394.8 |
| Other non-current assets | 169.1 | 151.8 |
| Total assets | $6,495.2 | $7,167.0 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $305.1 | $298.0 |
| Line of credit (current) | 400.0 | 400.0 |
| Share tracking awards plan | 29.2 | 35.4 |
| Other current liabilities | 126.3 | 71.0 |
| Total current liabilities | 860.6 | 804.4 |
| Line of credit (non-current) | 200.0 | 300.0 |
| Other non-current liabilities | 96.5 | 77.8 |
| Total liabilities | 1,157.1 | 1,182.2 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued | — | — |
| Common stock, par value $.01, 245,000,000 shares authorized, 74,098,932 and 73,659,761 shares issued, and 44,204,517 and 47,040,545 shares outstanding as of March 31, 2024 and December 31, 2023, respectively | 0.7 | 0.7 |
| Additional paid-in capital | 2,405.4 | 2,549.0 |
| Accumulated other comprehensive loss | (15.6) | (12.8) |
| Treasury stock, 29,894,415 and 26,619,216 shares as of March 31, 2024 and December 31, 2023, respectively | (3,386.1) | (2,579.2) |
| Retained earnings | 6,333.7 | 6,027.1 |
| Total stockholders’ equity | 5,338.1 | 5,984.8 |
| Total liabilities and stockholders’ equity | $6,495.2 | $7,167.0 |
| Quarterly Report | 3 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.